LFMD Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the LifeMD, Inc. Securities Fraud Class Action

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased LifeMD, Inc. (NASDAQ: LFMD) securities between May 7, 2025, and August 5, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that LifeMD's management materially overstated the company's competitive position [2]. - It is claimed that the company was reckless in raising its 2025 guidance without properly accounting for increasing customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - As a result, statements made by the defendants about LifeMD's business operations and prospects were materially false and misleading [2]. Financial Impact - On August 5, 2025, LifeMD revised its full-year 2025 guidance for revenue and adjusted EBITDA due to "temporary challenges" in its RexMD business, which led to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers with the court by October 27, 2025, and can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP has been a leader in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [5].